Screener / SEC EDGAR /CIK 0001368514 /10-K filed Feb 25, 2026, compared with Mar 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Adma Biologics, Inc. ADMA

Compare with peers Embed
The 10-K against last year's

143 changes: 27 added, 14 removed, 98 reworded, 4 quiet changes

10-K Feb 25, 2026 vs Mar 18, 2025

10-K 0001140361-26-006815 (Feb 25, 2026) vs 10-K 0001140361-25-009257 (Mar 18, 2025) Not compared: Legal Proceedings, Accounting Policies.

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

230 paragraphs · 10 new · 57 reworded · 1 gone · 10-K Feb 25, 2026 against Mar 18, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 207 · 39% changed Every version of it
expected timing and amount changes in our assessment of the release lack of any a need for a valuation allowance on our deferred tax assets; or
Paragraph 47 · 38% changed Every version of it
Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. In particular, the size and growth of the overall U.S. IVIG and source plasma markets and the potential market opportunity for an S. pneumoniae hyperimmune globulin are subject to significant variables that can be difficult to measure, estimate or quantify. Additionally, we anticipate receiving FDA approval by mid-2025 for the PAS for our innovative yield enhancement production process, which has demonstrated an ability to increase production yields by approximately 20% from the same starting plasma volume, potentially driving significant increases to financial targets beginning in the second half of 2025, if approved. Although our financial targets for 2025 and 2026 described in Part 1, Item 1. Business- Overview do not account for the potential FDA approval of our innovative yield enhancement production process, in the event that the FDA does not approve the PAS, or in the event that such approval occurs after mid-2025, our growth rate may be materially impacted.
Paragraph 187 · 38% changed Every version of it
The Healthcare Reform Law Inflation Reduction Act also created new rebate amended certain discount obligations for our products originally implemented under Medicare Part D, a partial, voluntary prescription drug benefit created by the U.S. federal government primarily for persons 65 years old and over. The Part D drug program is administered through private insurers that contract with CMS. Beginning in 2011, the Healthcare Reform Law generally Law. In January 2025, the Inflation Reduction Act implemented a new manufacturer discount program that requires that participating manufacturers to provide discounts on applicable drugs in order for a drug manufacturer’s products to be reimbursed under Medicare Part D, both the manufacturer must enter into a Medicare Initial Coverage Gap Discount Program agreement with the Secretary and Catastrophic Coverage phases of HHS, and reimburse each Medicare Part D plan sponsor an amount now equal to 70% savings for the manufacturer’s brand name drugs and biologics which the Part D plan sponsor has provided to its Medicare Part D beneficiaries who are in the “donut hole” (or a gap in Medicare Part D coverage for beneficiaries who have expended certain amounts for drugs). benefit. The Part D plan sponsor is responsible for calculating and providing the discount directly to its beneficiaries and for reporting these amounts paid to CMS’s contractor, which notifies drug manufacturers of the rebate amounts it must pay to each Part D plan sponsor. The rebate requirement could adversely affect our future financial performance, particularly if contracts with Part D plans cannot be favorably renegotiated or the Part D plan sponsors fail creating continued pressure to accurately calculate payments due in a manner that overstates our rebate obligation. lower prices related to units sold to Medicare beneficiaries. Regarding access to our products, the Healthcare Reform Law established and provided significant funding for a Patient-Centered Outcomes Research Institute to coordinate and fund Comparative Effectiveness Research (“CER”). While the stated intent of CER is to develop information to guide providers to the most efficacious therapies, outcomes of CER could influence the reimbursement or coverage for therapies that are determined to be less cost-effective than others. Should any of our products be determined to be less cost effective than alternative therapies, the levels of reimbursement for these products, or the willingness to reimburse at all, could be impacted, which could materially impact our future financial prospects and results.
Paragraph 182 · 38% changed Every version of it
The ACA and the companion Healthcare and Education Reconciliation Act (which together are referred to as the “Healthcare Reform Law”) introduced an abbreviated licensure pathway for biological products that are demonstrated to be biosimilar to an FDA-licensed biological product. A biological product may be demonstrated to be “biosimilar” if data shows that, among other things, the product is “highly similar” to an already-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. The law provides that a biosimilar application may be submitted as soon as four years after the reference product is first licensed, and that the FDA may not make approval of an application effective until 12 years after the reference product was first licensed. Since the enactment of the law, the FDA has issued several guidance documents This exclusivity period, however, is subject to assist sponsors of biosimilar products in preparing their approval applications. Moreover, in an effort to increase competition in the biologic product marketplace, Congress, the executive branch, and the FDA have taken certain legislative and regulatory steps. limitations. For example, the exclusivity only applies to the first licensure of a product, as defined in 2020 the statute and FDA finalized a guidance guidance, and, thus, not all BLAs will have exclusivity protection. There may also be future legislative efforts to facilitate biologic product importation. The 2020 Further Consolidated Appropriations Act included provisions requiring that sponsors decrease this period of approved biologic products provide samples of the approved products to persons developing biosimilar products within specified timeframes, in sufficient quantities, and on commercially reasonable market-based terms. exclusivity. The FDA approved the first biosimilar also may not consider a particular biologic to be a reference product in 2015 and has since approved a number of biosimilars. As a result of or competitors may pursue full traditional BLAs, rather than the biosimilar pathway in pathway, which full BLAs would not be blocked by the United States, regulatory exclusivity. Moreover, following the submission of a biosimilar application, we expect in the future may need to face greater competition from biosimilar products, including a possible increase in institute patent challenges. infringement actions or may be subject to actions for declaratory judgment, which may be time consuming and costly.
Paragraph 183 · 30% changed Every version of it
The ACA and the companion Healthcare and Education Reconciliation Act (which together are referred to as the “Healthcare Reform Law”) introduced an abbreviated licensure pathway for biological products that are demonstrated to be biosimilar to an FDA-licensed biological product. A biological product may be demonstrated to be “biosimilar” if data shows that, among other things, the product is “highly similar” to an already-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. The law provides that a biosimilar application may be submitted as soon as four years after the reference product is first licensed, and that the FDA may not make approval of an application effective until 12 years after the reference product was first licensed. Since the enactment of the law, the FDA has issued several guidance documents to assist sponsors of biosimilar products in preparing their approval applications. Moreover, in an effort to increase competition in the biologic product marketplace, Congress, the executive branch, and the FDA have taken certain legislative and regulatory steps. For example, in 2020 the FDA finalized a guidance to facilitate biologic product importation. The 2020 Further Consolidated Appropriations Act included provisions requiring that sponsors of approved biologic products provide samples of the approved products to persons developing biosimilar products within specified timeframes, in sufficient quantities, and on commercially reasonable market-based terms. In 2025, the FDA also potentially made it easier for sponsors of biosimilar or interchangeable products to obtain approval, easing requirements for biosimilar comparative efficacy clinical studies and interchangeable product switching studies. The FDA approved the first biosimilar product in 2015 and has since approved a number of biosimilars. As a result of the biosimilar pathway in the United States, we expect in the future to face greater competition from biosimilar products, including a possible increase in patent challenges.
Paragraph 95 · 26% changed Every version of it
We currently anticipate expanding the may expand our manufacturing capacity and product output capability of our the Boca Facility. Following the expansion of any of our manufacturing processes or the addition of new equipment, such as our fill-finish machine, we will need be required to validate the expanded facility facility, process changes if any and equipment, make the necessary submissions to FDA, obtain any FDA-required approvals and have it inspected by the FDA. Any other changes to the manufacturing process will also potentially require validation, FDA submissions, and approvals and inspections. Changes may also require that further studies are conducted before the change is approved by regulatory authorities or product marketing approval is obtained. Given the significant delays that may result during the validation and approval process, we may not receive the necessary manufacturing or product approvals, experience a supply shortage of our products or our production capabilities may be limited until completion of and validation of our facility expansion and new manufacturing equipment. equipment and until the necessary approvals are obtained.
Paragraph 131 · 26% changed Every version of it
On December 18, 2023 (the “Ares Closing Date”), we entered into a credit agreement with Ares (the “Ares Credit Agreement”) (see “Liquidity and Capital Resources”). The Ares Credit Agreement provided for a total of $135 million in senior secured credit facilities (the “Ares Credit Facility”) consisting of (i) a term loan in the aggregate principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal amount of $72.5 million (collectively, the “Ares Loans”), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility has a maturity date of December 20, 2027 (the “Ares Maturity Date”). On August 14, 2024, we repaid $30.0 million against the revolving credit facility and on December 19, 2024 we repaid $30.0 million against the term loan. As of December 31, 2024, we had $42.5 million and $32.5 million of borrowings outstanding under the revolving credit facility and the term loan, respectively. The Ares JPM Loans are secured by substantially all of our assets, including our intellectual property. Events of default include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, we would incur an increase in the rate of interest on the Ares JPM Loans of 2% per annum. The occurrence of an event of default could result in, among other things, the termination of commitments under the Ares JPM Credit Facility, Facilities, the declaration that all outstanding loans are immediately due and payable in whole or in part, and Ares JPMorgan taking immediate possession of, and selling, any collateral securing the Ares JPM Loans.
Paragraph 18 · 25% changed Every version of it
Our senior secured credit facility with Ares Capital Corporation JPMorgan Chase Bank, N.A. and certain of its affiliates (“Ares”) other lenders party thereto (collectively “JPMorgan”) is subject to acceleration in specified circumstances, which may result in Ares JPMorgan taking possession and disposing of any collateral.

MD&A

89 paragraphs · 17 new · 56 reworded · 13 gone · 10-K Feb 25, 2026 against Mar 18, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 34 · 50% changed
Selling, general and administrative (“SG&A”) expenses were $59.0 $91.6 million for the year ended December 31, 2023, 2025, an increase of $6.6 $17.5 million from the year ended December 31, 2022. 2024, or approximately 24%. The increase reflects is primarily driven by higher compensation costs due to increased headcount to support the growth of our business and manufacturing operations. In addition, higher insurance premiums, professional fees and software expenses for employee-related costs including salaries, benefits, stock-based compensation, travel, relocation and recruiting of $2.4 million, data services and market intelligence fees in support of the continued ASCENIV and BIVIGAM commercialization efforts in the amount of $1.8 million, marketing and advertising expenses of $1.0 million, insurance expense of $0.6 million, software maintenance expense of $0.6 million and state and local taxes of $0.2 million. contributed to this increase.
Paragraph 86 · 50% changed
Research and development (“R&D”) expenses totaled $1.8 million Cash used in investing activities for the year ended December 31, 2024, 2025, was $21.9 million as compared to $3.3 million cash used in investing activities for the year ended December 31, 2023. 2024 of $8.6 million. The decrease increase is primarily due to the absence of expenditures in 2024 related to the BIVIGAM post-marketing commitments, for which we incurred $1.7 million of expenses in 2023, partially offset by an increase in expenses capital expenditures associated with our ASCENIV pediatric study the Yield Enhancement project of $1.8 million and the acquisition of the real estate in Boca Raton, FL in the amount of $0.3 million. $12.6 million, partially offset by the $1.0 million deposit received in December 2025 related to the sale of three of our plasma centers (refer to Note 5 to our financial statements included in Item 8 of this Annual Report on Form 10-K for further information).
Paragraph 76 · 50% changed
On August 14, 2024, In May 2025, we repaid $30.0 million against the revolving credit facility and the outstanding balance on the revolving credit facility as Ares term loan using a draw of December 31, 2024 was $42.5 million. On December 19, 2024 we repaid $30.0 million against the term loan and Ares revolving credit facility made in May 2025. In August 2025, we repaid all obligations outstanding under the outstanding balance on Ares Credit Agreement using the term loan as proceeds from the JPM Credit Agreement, defined below. As a result of the aforementioned transactions, during the year ended December 31, 2024 was $32.5 million. In connection with the repayment against the term loan, 2025, we recognized a loss on debt extinguishment losses of debt in the approximate amount of $1.2 million, which is comprised of a prepayment penalty in the amount of $0.45 million and a partial write-off of unamortized discount attributable to the term loan in the amount of $0.8 $3.3 million.
Paragraph 72 · 49% changed
On August 14, 2024, we repaid $30.0 million against the Ares revolving credit facility and the outstanding balance on the Ares revolving credit facility as of December 31, 2024 was $42.5 million. On December 19, 2024 we repaid million, with an additional $30.0 million against of availability through the term loan and the outstanding balance on the term loan as Ares Maturity Date. We were required to pay an unused commitment fee of December 31, 2024 was $32.5 million. In connection with the repayment against the term loan, we recognized a loss on extinguishment of debt in the approximate amount of $1.2 million, which is comprised of a prepayment penalty in the amount of $0.45 million and a partial write-off of unamortized discount attributable to the term loan in the amount of $0.8 million. 0.5% per annum for this availability.
Paragraph 62 · 49% changed
Amortization expense mainly pertains to Excludes estimated tax effect of the amortization add-backs of intangible assets acquired in a 2017 acquisition transaction and was $0.7 $2.7 million $0.6 million for the years ended December 31, 2023 2025 and 2022. 2024, respectively.
Paragraph 35 · 46% changed
Our net loss Interest expense for the year ended December 31, 2025, was $28.2 $7.1 million, as compared to $13.9 million for the year ended December 31, 2023, as compared to $65.9 million for 2024, primarily driven by the year ended December 31, 2022. The $37.7 million decrease in net loss was mainly debt balances due to the improvement principal repayments made in operating income/loss of $61.0 million 2024 and the $1.9 million increase in other income/expense, partially offset by a higher loss on extinguishment of debt of $19.5 million and higher lower JPM Term Loan Facility (as defined below) interest expense of $5.7 million. rate.
Paragraph 26 · 46% changed
Other income, net, for the year ended December 31, 2024 was $1.9 million, as compared to $1.3 We recorded total revenues of $510.2 million for the year ended December 31, 2023. The increase is mainly due 2025, as compared to $426.5 million for the year ended December 31, 2024, an increase in interest income of $0.5 million in $83.7 million, or 20%. Revenue by product for the years ended December 31, 2025 and 2024 resulting from higher average cash balances in 2024. was as follows:
Paragraph 41 · 46% changed
Other income, net, for the year ended December 31, 2024 was $1.9 million, as compared to $1.3 We recorded total revenues of $426.5 million for the year ended December 31, 2023. The increase is mainly due 2024, as compared to $258.2 million for the year ended December 31, 2023, an increase in interest income of $0.5 million in $168.2 million, or 65%. Revenue by product for the years ended December 31, 2024 resulting from higher average cash balances in 2024. and 2023 was as follows:

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors271 words changed in this paragraph; it is 49% similar to last year's version.
The Healthcare Reform Law Inflation Reduction Act also created new rebate amended certain discount obligations for our products originally implemented under Medicare Part D, a partial, voluntary prescription drug benefit created by the U.S. federal government primarily for persons 65 years old and over. The Part D drug program is administered through private insurers that contract with CMS. Beginning in 2011, the Healthcare Reform Law generally Law. In January 2025, the Inflation Reduction Act implemented a new manufacturer discount program that requires that participating manufacturers to provide discounts on applicable drugs in order for a drug manufacturer’s products to be reimbursed under Medicare Part D, both the manufacturer must enter into a Medicare Initial Coverage Gap Discount Program agreement with the Secretary and Catastrophic Coverage phases of HHS, and reimburse each Medicare Part D plan sponsor an amount now equal to 70% savings for the manufacturer’s brand name drugs and biologics which the Part D plan sponsor has provided to its Medicare Part D beneficiaries who are in the “donut hole” (or a gap in Medicare Part D coverage for beneficiaries who have expended certain amounts for drugs). benefit. The Part D plan sponsor is responsible for calculating and providing the discount directly to its beneficiaries and for reporting these amounts paid to CMS’s contractor, which notifies drug manufacturers of the rebate amounts it must pay to each Part D plan sponsor. The rebate requirement could adversely affect our future financial performance, particularly if contracts with Part D plans cannot be favorably renegotiated or the Part D plan sponsors fail creating continued pressure to accurately calculate payments due in a manner that overstates our rebate obligation. lower prices related to units sold to Medicare beneficiaries. Regarding access to our products, the Healthcare Reform Law established and provided significant funding for a Patient-Centered Outcomes Research Institute to coordinate and fund Comparative Effectiveness Research (“CER”). While the stated intent of CER is to develop information to guide providers to the most efficacious therapies, outcomes of CER could influence the reimbursement or coverage for therapies that are determined to be less cost-effective than others. Should any of our products be determined to be less cost effective than alternative therapies, the levels of reimbursement for these products, or the willingness to reimburse at all, could be impacted, which could materially impact our future financial prospects and results.

Source: Item 1A, 10-K 0001140361-26-006815 vs Item 1A, 10-K 0001140361-25-009257

MD&A245 words changed in this paragraph; it is 30% similar to last year's version.
We recorded The increase in total revenues of $426.5 million for the year ended December 31, 2024, as compared to $258.2 million for the year ended December 31, 2023, an increase of $168.2 million, or 65%. Excluding the $12.6 million adjustment we recorded in the second quarter of 2024 to decrease our accrual for estimated U.S. Medicaid rebates (which had the effect of increasing net revenues by $12.6 million), revenue increased by approximately $155.6 million, or 60%. This increase is primarily related to increased sales of ASCENIV, as we continue to experience increased physician, payer and patient acceptance and utilization of this product, as well as partially offset by the decrease in sales increases for some of our other IG products. BIVIGAM, intermediates and other. The revenue increase also includes an increase in sales of normal source plasma (“NSP”) and hyperimmune Hepatitis B plasma by our Plasma Collection Centers business segment in the amount of $2.2 $6.5 million. During the year ended December 31, 2025, and as previously disclosed in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, we voluntarily withdrew three lots of BIVIGAM (such a withdrawal, hereinafter referred to as the “Voluntary Withdrawal”) as a precautionary measure. This resulted in a reduction in revenue recognized for the year ended December 31, 2025 of $4.0 million for credits issued to customers that were impacted by this Voluntary Withdrawal. This action was proactively initiated, and we believe this matter to be resolved. Excluding the $12.6 million adjustment we recorded in 2024 to decrease our accrual for estimated U.S. Medicaid rebates (which had the effect of increasing net revenues by $12.6 million during the year ended December 31, 2024), total revenue increased by approximately $96.3 million, or 23%.

Source: Item 7, 10-K 0001140361-26-006815 vs Item 7, 10-K 0001140361-25-009257

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of ADMA's Risk Factors and MD&A, 10-K Feb 25, 2026 against 10-K Mar 18, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Regulatory authorities may not accept data from foreign clinical studies or sites or may find that such data is not sufficiently representative of the population of the approving jurisdiction;
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
On August 5, 2025 (the “JPM Closing Date”), we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM Credit Agreement”) (see “Liquidity and Capital Resources”). The JPM Credit Agreement provides for a total of $300 million in senior secured credit facilities (the “JPM Credit Facilities”) consisting of (i) a term loan in the aggregate principal amount of $75 million, which was drawn in full on the JPM Closing Date, and (ii) a revolving credit facility in the aggregate principal amount of up to $225 million (collectively, the “JPM Loans”), none of which was drawn on the JPM Closing Date. The JPM Credit Facility has a maturity date of August 5, 2028.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
There is no assurance that ASCENIV, or any other of our products for which we are issued a patent, will enjoy market exclusivity for the full time period of the respective patent.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
We have engaged a third-party firm to assist the Company with the development and deployment of an AI tool, ADMAlytics, to improve efficiencies across our supply chain, production, and commercial operations. This tool has been used to assist with activities including plasma pool composition and identifying other manufacturing efficiencies to streamline certain operational processes. While we have successfully implemented ADMAlytics in certain aspects of our commercial manufacturing and expanded its use throughout fiscal year 2025, the development, implementation, and ongoing use of AI technologies involve inherent risks. While ADMA has not experienced any issues to date, these risks include potential data inaccuracies, flawed assumptions, system errors, cybersecurity vulnerabilities, unintended outcomes, and difficulties in integrating AI-driven insights into complex and highly regulated manufacturing and operational environments. If ADMAlytics fails to perform as intended or produces unreliable or biased outputs, our reputation could be harmed and we could be subject to legal exposure, which could adversely affect our business, results of operations, and financial condition.
Read it in 10-K Feb 25, 2026 at sec.gov
Show the other 55
AddedRisk Factors
We may face new risks as a result of changes in legal and regulatory requirements that may impact our operations and future prospects. For example, the 2025 change in the U.S. federal administration, as well as changes in legal standards, including the reduced level of judicial deference due to administrative agencies following a 2024 Supreme Court decision, may and does introduce regulatory and legal uncertainties that impact our operations. New federal or state laws and regulations may be, and have been, passed or enforced differently than they were before, requiring that we adapt, which we may not be able to do, and expend additional resources to ensure that we are able to comply. New laws and regulations, or the enforcement of the same, may also adversely restrict how we conduct our business. There could also be changes in the FDA’s approval standards that could impact our ability to obtain and maintain product approvals and market our product candidates or that otherwise could impact the competitive market for our products. Legal and regulatory changes may additionally impact how we may market and sell our products and how they are reimbursed. We cannot predict the exact nature of any changes that may take place or whether and how they may impact our business and results of operation.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
In addition, our effective tax rate in a given financial statement period may be materially impacted by a variety of other factors including, but not limited to, changes in the mix and level of earnings, deductible expenses and availability of NOLs changes in the different states and other jurisdictions in which we operate, fluctuations in and deductible expenses and limitations on the valuation allowance on our deferred tax assets, or by changes to existing accounting rules or regulations. use of NOLs resulting from ownership changes.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
Violations of laws such as the FDCA, the Social Security Act (including the Anti-Kickback Statute), the Public Health Service Act, the civil and criminal federal False Claims Act, the civil monetary penalty statute, requirements regarding the reporting and repayment of overpayments, other fraud and abuse laws and any regulations promulgated under the authority of the preceding, may result in significant criminal and/or civil sanctions, including jail sentences, fines or criminal fines, imprisonment, civil monetary penalties and damages, exclusion from participation in or federal healthcare programs (including Medicare and Medicaid), suspension and debarment from federal government contracts, and state healthcare or refusal of orders under existing government procurement programs, contracts, pursuant to enforcement actions by DOJ, Medicare, Medicaid, CMS, OIG and other regulatory authorities.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
In addition, any such litigation may divert our management's attention from our core business and reduce the resources available for our clinical development, manufacturing and marketing activities, and consequently have a material and adverse effect on our business and prospects, regardless of the outcome.There is no assurance that ASCENIV, or any other of our products for which we are issued a patent, will enjoy market exclusivity for the full time period of the respective patent. outcome.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
Although we achieved net income of $197.7 million and $146.9 million for the years ended December 31, 2024 and 2025, respectively, for the year ended December 31, 2024, for the years ended December 31, 2023 and 2022, we incurred a net losses loss of $28.2 million and $65.9 million, respectively. million.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
Depending on the seriousness of any findings, we or our suppliers may be subject to additional significant enforcement or other actions and events, may need to undertake product recalls, may have a disruption in the supply of commercial or clinical product, or may need to modify or repeat studies, which could have a material impact on our business.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
Further, there can be no assurance that we will be able to generate the revenue that we believe our products and plasma collection facilities are capable of generating. generating, including but not limited to our current expectations with respect to our yield enhancement production process, which received FDA approval in April 2025.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
As of December 31, 2024, 2025, there were 36,093,118 38,703,218 shares of common stock remaining available for issuance, after giving effect to 11,854,060 9,827,286 shares of our common stock that were subject to outstanding stock options, options and RSUs and warrants as of December 31, 2024 that may be issued by us without stockholder approval, as well as an additional 15,432,277 13,595,000 shares of our common stock reserved for the future issuance of awards under our equity compensation plans.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
We have employment agreements with each of our executive officers; however, the existence of an employment agreement does not guarantee retention of members of our management team and we may not be able to retain those individuals for the duration of or beyond the end of their respective terms. team.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
Our operations, including our headquarters located in Ramsey, NJ, the Boca Facility Facility, our new real estate in Boca Raton, FL and our plasma collection facilities, are vulnerable to natural disasters (including as a result of climate change), such as interruption by fire, fires, weather related events such as hurricanes, wind and rain, other acts of God or force majeure events, electric power loss, telecommunications failure, equipment failure and breakdown, cyberattacks on our operations and information technology systems as well as the systems of our customers, suppliers and related entities, human error, employee issues, global health occurrences such as a pandemic, global and economic uncertainty, war, terrorism, geopolitical conditions and emergencies, product liability claims and events beyond our control.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
As of March 10, 2025, February 20, 2026, most of our 237,615,100 238,159,176 outstanding shares of common stock, as well as a substantial number of shares of our common stock underlying outstanding warrants, were available for sale in the public market, subject to certain restrictions with respect to sales of our common stock by our affiliates, either pursuant to Rule 144 under the Securities Act, or under effective registration statements.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
In addition, our contract fill/finishers and our other third-party vendors may source their materials and supplies globally and are therefore subject to potential tariffs, which could be passed along to us in whole or in part and adversely impact our results of operations, and supply disruptions in the event of fire, weather related events such as hurricanes, wind and rain, international conflicts, strikes, embargoes, trade and sanction requirements and limits, other acts of God or force majeure events or global health occurrences and emergencies.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
Our senior secured credit facility with Ares Capital Corporation JPMorgan Chase Bank, N.A. and certain of its affiliates (“Ares”) other lenders party thereto (collectively “JPMorgan”) is subject to acceleration in specified circumstances, which may result in Ares JPMorgan taking possession and disposing of any collateral.
Read it in 10-K Feb 25, 2026 at sec.gov
Quiet changesRisk Factors
Under the Healthcare Reform Law, payments and transfers of value by pharmaceutical manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to or at the request of covered recipients, such as, but not limited to, U.S.-licensed physicians, physician assistants, nurse practitioners, clinical nurse specialists and certified registered nurse anesthetists and U.S. teaching hospitals, must be tracked and reported to CMS, and are publicly disclosed.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
In April 2025, the FDA approved our Prior Approval Supplement (the “PAS”) for our innovative yield enhancement production process (the “Yield Enhancement”) benefiting both ASCENIV and BIVIGAM. This PAS approval amends the Biologics License Application (“BLA”) approvals for ASCENIV and BIVIGAM and will continue to be the process by which we will manufacture these products on a go-forward basis. The production methods approved in this PAS have started to result in additional bulk drug yield from the same starting raw material source plasma volumes and the Company believes it should experience meaningful revenue and earnings accretion accelerating further into 2026 and beyond. This innovative process has demonstrated an ability to increase ASCENIV and BIVIGAM production yields by 20% or more from the same starting source plasma volume. Fiscal year 2026 will be our first full year of yield-enhanced production, supporting anticipated sustained margin expansion.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
In July 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted, which includes numerous changes to existing tax law including extending or making permanent certain business provisions initially established under the 2017 Tax Cuts and Jobs Act, which were set to expire. The OBBBA permanently eliminates the requirement to capitalize and amortize U.S.-based research and experimental expenditures, making these expenditures fully deductible in the period incurred. The OBBBA also permanently extends recognition of the accelerated bonus depreciation on qualifying assets in the period acquired. In 2025, these provisions resulted in a reduction of current income tax liabilities and a corresponding reduction to income tax expense.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
In July 2025, we completed the acquisition of real estate in Boca Raton, FL for a total purchase price of $12.6 million. This real estate purchase is intended to allow us to expand our production operations and related activities as well as provide for certain redundancies for ambient and cold-chain storage of raw materials, work in process and finished goods inventory.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
In December 2025, we entered into an agreement for the divestiture of three of our plasma collection centers for an aggregate purchase price of $12.0 million. As of the date of this Annual Report on Form 10-K, two of the plasma collection centers have been sold to the purchaser. The closing of the third center is anticipated to occur in the first quarter of 2026. After the divestiture of all three centers, we will continue to own and operate seven plasma collection centers. In conjunction with the divestiture agreement, we entered into long-term plasma supply agreements with the purchaser of the three plasma collection centers, further diversifying our third-party high-titer plasma supply base. Collectively, these actions reflect a deliberate shift toward a more flexible, capital-efficient supply model and are expected to deliver accretive cost savings beginning in fiscal year 2026, improve capital efficiency, support increased ASCENIV production capacity, and provide durable plasma supply confidence through the late 2030s.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
Our provision for income taxes and the determination of our effective tax rate are subject to significant judgment and complexity. We estimate our income tax expense based on enacted tax laws and statutory tax rates in the jurisdictions in which we operate, as well as our interpretation of relevant tax regulations. The effective tax rate includes the impact of various estimates and judgments. Changes in these estimates or in tax laws could significantly affect our effective tax rate and results of operations. Due to the complexity of tax regulations and the potential for differing interpretations, it is reasonably possible that the ultimate resolution of these matters could result in material adjustments to our effective tax rate in future periods.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
(1) Due to Nabi-HB historically representing less than 10% of the Company’s revenue within the ADMA BioManufacturing segment, it has been included under intermediates and other products. The $12.6 million U.S. Medicaid rebate adjustment recorded in 2024 is also included under intermediates and other products.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
Income tax expense of $35.7 million for the year ended December 31, 2025 represented an effective tax rate of 19.6%, which differed from the federal statutory rate of 21% primarily due to the excess tax benefits on stock-based compensation and R&D tax credits.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
(1) Due to Nabi-HB historically representing less than 10% of the Company’s revenue within the ADMA BioManufacturing segment, it has been included under intermediates and other products. The $12.6 million U.S. Medicaid rebate adjustment recorded in 2024 is also included under intermediates and other products.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
We currently anticipate, based upon our projected revenue and expenditures, that our current cash, cash equivalents and accounts receivable, along with our projected future operating cash flow, will be sufficient to fund our operations, as currently conducted, through the first quarter of 2027 and beyond. Based on current operations and assuming continued market acceptance and utilization of our finished drug products, we do not anticipate the need to raise additional capital at this time. However, should the market for our products or political, economic or inflationary conditions change, we may need to seek additional capital which may not be available due to a variety of potential factors beyond our control (see “Risk Factors” appearing elsewhere in this report).
Read it in 10-K Feb 25, 2026 at sec.gov
RemovedMD&A
In December 2024, we successfully submitted a Prior Approval Supplement (the “PAS”) for potential approval of our innovative yield enhancement production process. Following FDA review of the submission, we anticipate receiving FDA approval by mid-2025, with potential revenue and earnings accretion expected in the second half of the year. This innovative process has demonstrated an ability to increase production yields by approximately 20% from the same starting plasma volume, potentially driving significant increases to financial targets, if approved.
Read it in 10-K Mar 18, 2025 at sec.gov
RemovedMD&A
Prior to 2024, adjustments to these estimates to reflect actual results or updated expectations have not been material to our overall business. While we have some historical sales and rebate experience from our two primary immunoglobulin products, ASCENIV and BIVIGAM, since their FDA approvals in 2019, our historical experience is not extensive. If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate estimates of our future experience, our results could be materially affected. Estimates that are most at risk for material adjustment are those associated with U.S. Medicaid rebates because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally take up to several years or more. These estimates may change from time to time based on changes in utilization, payer and channel mixes. During 2024, we engaged a third-party specialist to assist in the evaluation of our accrual for U.S. Medicaid rebates related to the sale of our immunoglobulin products. As a result of this evaluation, we recognized a reduction in this accrual and a corresponding increase to net revenues of $12.6 million during the year ended December 31, 2024 (see Note 2 to the Consolidated Financial Statements). We considered several qualitative factors when evaluating our rebate accrual, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. There was additional new information that arose during June 2024 that suggested our liabilities for certain payor claims were successfully resolved, which resulted in the $12.6 million adjustment to the accrual for U.S. Medicaid rebates in June 2024. Additional changes in estimate assumptions surrounding U.S. Medicaid and other rebate obligations could materially impact our revenues and our results of operations in the future.
Read it in 10-K Mar 18, 2025 at sec.gov
RemovedMD&A
All equity-based payments, including grants of stock options and restricted stock units (“RSUs”), are recognized at their estimated fair value at the date of grant, and compensation expense is recognized on a straight-line basis over the grantee’s requisite vesting period. For the purpose of valuing stock options granted to our employees, directors and executive officers, we use the Black-Scholes option pricing model. We also use the Black-Scholes model when determining additional compensation cost resulting from the modification to previously issued option grants. The Black-Scholes option pricing model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. The Company’s employee stock options have characteristics significantly different from those of traded options, and changes in the underlying Black-Scholes assumptions can materially affect the fair value estimate. To determine the risk-free interest rate, we utilize the U.S. Treasury yield curve in effect at the time of the grant with a term consistent with the term of our awards. The expected term of the options granted is in accordance with U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletins 107 and 110 and is based on the average between vesting terms and contractual terms. The expected dividend yield reflects our current and expected future policy for dividends on our common stock. The expected stock price volatility for our stock options was calculated by examining the historical volatility of our common stock since our common stock became publicly traded. We will continue to analyze the expected stock price volatility and expected term assumptions and will adjust our Black-Scholes option pricing assumptions as appropriate. Any changes in the foregoing Black-Scholes assumptions, or our election to utilize an alternative method for valuing stock options granted to employees, directors and executive officers, could potentially impact our stock-based compensation expense and our results of operations.
Read it in 10-K Mar 18, 2025 at sec.gov
RemovedMD&A
Prior to December 31, 2024, we maintained a full valuation allowance against all of our net deferred tax assets, and as a result we have historically not recorded an income tax benefit in the accompanying consolidated financial statements despite continued losses through December 31, 2023. This valuation allowance reflected our assessment of whether it is more likely than not that we would generate sufficient taxable income in the future to be able to utilize our deferred tax assets. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies. We consider all positive and negative evidence to estimate if sufficient future taxable income will be generated to realize our deferred tax assets, and we considered cumulative losses in recent years to be a significant type of negative evidence. As of December 31, 2024, we determined that it is more-likely-than-not that our federal and state deferred tax assets will be realized. As a result, we recorded a release of the valuation allowance associated with these deferred tax assets, which was due in part to achieving three years of cumulative taxable income and projected taxable income that is more than sufficient to realize our federal and state deferred tax assets, and we recorded a deferred income tax benefit in the amount of $84.3 million for the year ended December 31, 2024 (see Note 11 to the consolidated financial statements).
Read it in 10-K Mar 18, 2025 at sec.gov
RemovedMD&A
Plasma Center Operating Expenses decreased from $17.8 million in the year ended December 31, 2022 to $4.3 million in the year ended December 31, 2023. As a result of our now having ten plasma centers in operation, we were able to more than double the number of liters of plasma collected, with a corresponding reduction in the cost per liter, in 2023 as compared to 2022, coupled with the changes in the market price of normal source plasma and its impact on the net realizable value of our plasma inventory, the amount of plasma center costs we capitalized into inventory increased by approximately $43.2 million in 2023. This amount was largely offset by increases in donor fees of $12.8 million, compensation, benefits and temporary labor of $3.9 million, softgoods and supplies of $5.0 million, donor testing expenses of $4.8 million, depreciation of $0.8 million, software maintenance expense of $0.9 million, janitorial, security and utilities expense of $0.5 million, travel expenses of $0.1 million, advertising expense of $0.2 million, repairs and maintenance expense of $0.2 million and rent of $0.2 million. In addition, our plasma center collections and operating costs were unfavorably impacted by approximately $0.7 million due to the temporary closing of our plasma collection centers attributable to an IT disruption occurring in June 2023, of which all systems have since been fully restored.
Read it in 10-K Mar 18, 2025 at sec.gov
RemovedMD&A
For the year ended December 31, 2024, we had pre-tax income and GAAP net income of $125.7 million and $197.7 million, respectively. We currently anticipate, based upon our projected revenue and expenditures, that our current cash, cash equivalents and accounts receivable, along with our projected future operating cash flow, will be sufficient to fund our operations, as currently conducted, through the end of the first quarter of fiscal 2026. However, our current outlook with respect to cash flows and profitability may change based upon several factors, including the continued success of our commercial efforts with respect to the sale of our products and the continued acceptability of our immune globulin products by physicians, patients or payers, and whether or not the assumptions underlying our projected revenues and expenses are correct. If we are unable to maintain positive cash flow throughout fiscal 2025, we may choose to raise additional capital. If we are unable to generate sufficient revenue to maintain positive cash flow throughout fiscal 2025 and elect to raise additional capital, we may decide to do so through public or private equity offerings or debt financings, or we may enter into a corporate collaboration or licensing arrangement. The sale of additional equity securities or debt financings, if convertible, could result in dilution to our stockholders and, in such event, the value and potential future market price of our common stock may decline.
Read it in 10-K Mar 18, 2025 at sec.gov
RemovedMD&A
In connection with the closing of the Ares Credit Facility, we incurred fees and expenses related to the transaction of approximately $2.7 million, including a $1.7 million original issue discount payable to Ares, all of which was deducted from the Ares loan proceeds. In addition, we are also required to pay Ares an exit fee of $1.7 million upon the earlier of any prepayment date or the Ares Maturity Date, and this obligation has been accrued as a separate liability in our consolidated balance sheet as of December 31, 2024 and 2023 in the amount of $1.3 million and $1.7 million, respectively. As a result, we recognized an aggregate debt discount of $4.4 million as of the Ares Closing Date, and the weighted-average effective interest rate on the Ares Loans as of December 31, 2024 and 2023 was 10.81% and 11.39%, respectively. In connection with the prepayment of the term loan on December 19, 2024, we also paid a pro rata portion of the exit fee in the amount of $0.4 million.
Read it in 10-K Mar 18, 2025 at sec.gov
RemovedMD&A
Events of default on the Ares Loans include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, we will incur an increase in the rate of interest on the Ares Loans of 2% per annum.
Read it in 10-K Mar 18, 2025 at sec.gov
RemovedMD&A
On March 23, 2022 (the “Hayfin Closing Date”), we and all of our subsidiaries entered into the Hayfin Credit Agreement with Hayfin. The Hayfin Credit Agreement, as amended, provided for a senior secured term loan facility in a principal amount of up to $175.0 million, composed of (i) a term loan made on the Hayfin Closing Date in the principal amount of $150.0 million (the “Hayfin Closing Date Loan”), and (ii) a delayed draw term loan in the principal amount of $25.0 million (the “Hayfin Delayed Draw Loan” and, together with the Hayfin Closing Date Loan, the “Hayfin Loans”). The Hayfin Delayed Draw Loan was not drawn prior to our termination of the Hayfin Credit Agreement. The Hayfin Credit Facility had a maturity date of March 23, 2027 (the “Hayfin Maturity Date”), subject to acceleration pursuant to the Hayfin Credit Agreement, including upon an Event of Default (as defined in the Hayfin Credit Agreement).
Read it in 10-K Mar 18, 2025 at sec.gov
RemovedMD&A
On the Hayfin Closing Date, we used $100.0 million of the Hayfin Closing Date Loan to terminate and pay in full all of the outstanding obligations under our previous senior credit facility with Perceptive (see Note 7 to the Consolidated Financial Statements). We also used $2.0 million of the Hayfin Closing Date Loan proceeds to pay a redemption premium to Perceptive and used approximately $1.0 million of the Hayfin Closing Date Loan proceeds to pay certain fees and expenses incurred in connection with this transaction. In addition, a $1.8 million upfront fee payable to Hayfin was paid “in kind” and was added to the outstanding principal balance in accordance with the terms of the Hayfin Credit Agreement.
Read it in 10-K Mar 18, 2025 at sec.gov
RemovedMD&A
Borrowings under the Hayfin Credit Agreement bore interest at the adjusted Term SOFR for either a one-month or three-month tenor, as elected by us, and subject to a floor of 1.25%, plus an applicable margin of 9.5% (the “Applicable Margin”); provided, however, that upon, and during the continuance of, an Event of Default, the Applicable Margin would increase by an additional 3% per annum. On May 1, 2023 the Hayfin Credit Agreement was amended to reduce the Applicable Margin from 9.5% to 8.5%. On the last day of each calendar month prior to the Ares Closing Date we paid accrued interest to Hayfin. On the Hayfin Closing Date, December 31, 2022 and the Ares Closing Date, the stated interest rate on the Hayfin Loans was 10.75%, approximately 13.7% and approximately 13.9%, respectively. We were also permitted to pay “in kind” a portion of the interest on the Hayfin Loans for each monthly interest period in an amount equal to 2.5% per annum, which was added to the principal amount of the outstanding debt under the Hayfin Credit Facility. From the Hayfin Closing Date through December 31, 2022, $3.0 million of interest was paid in kind and added to the balance of the outstanding Hayfin Loans. For the year ended December 31, 2023, $3.8 million of interest was paid in kind and added to the balance of the outstanding Hayfin Loans.
Read it in 10-K Mar 18, 2025 at sec.gov
RemovedMD&A
On the Ares Closing Date, we paid Hayfin the entire outstanding principal amount underlying the Hayfin Loans and any accrued and unpaid interest thereon, as well as an exit fee of 1.0% of the outstanding principal amount being paid. In accordance with the terms of the Hayfin Credit Agreement, we also paid Hayfin the early prepayment fee in the amount equal 7.0% of the prepaid principal amount, or $11.1 million.
Read it in 10-K Mar 18, 2025 at sec.gov
RewordedMD&A
The negative covenants include certain financial covenants, including maximum total leverage ratios and a $15.0 million liquidity covenant, and also restrict or limit our ability and the ability of our subsidiaries to, among other things and subject to certain exceptions contained in the Ares JPM Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to our or our subsidiaries’ business activities; changes; make certain Investments investments; dispose of certain assets; engage in sale and leaseback transactions or swap agreements; make certain Restricted Payments (each as (as defined in the Ares JPM Credit Agreement); engage in certain affiliate transactions; or enter into, amend or terminate into any other agreements that have the impact of restricting our ability to make loan repayments under the Ares JPM Credit Agreement. Agreement; or amend certain material documents.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
We may prepay The Ares Credit Agreement permitted prepayment of the outstanding principal on the term loan, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon three business days’ prior written notice, subject to the payment to Ares of a prepayment premium equal to (i) the present value as of such date of all remaining required interest payments on the principal amount being repaid plus 1.5% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) 1.5% of the prepaid principal amount, if prepaid after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, Date or (iii) (ii) 1.0% of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Years Year Ended December 31, 2025 2024 2023 (in thousands) 2024 2023 2022 Net income (loss) $ 146,930 $ 197,673 $ (28,239) $ (65,904) Loss on extinguishment of debt 3,336 1,243 26,174 6,670 Deferred tax benefit - (84,280) - - Yield enhancement 2,064 - - Stock-based compenstion modifications 757 2,518 - Yield Enhancement expense 1,810 2,064 - IT systems disruption Voluntary Withdrawal and product replacements 6,215 - - Non-recurring professional fees (pre-tax) 1,781 - 2,770 - (a) Adjusted net income (loss) income(b) $ 160,829 $ 119,218 $ 705 $ (59,234)
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
This The increase is primarily attributable due to volume-driven increases in product revenue costs related to higher volume of our increased sales of IG products and plasma plasma, which impacted cost of $39.5 product revenue by $19.7 million and $3.1 $6.7 million, respectively, partially offset by $10.2 million driven by lower volume of intermediates and other, and a reduction in other manufacturing costs, mainly unabsorbed manufacturing expenses, expenses of $5.1 $5.7 million.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Plasma center operating expenses, which primarily consists consist of compensation, benefits and travel for plasma center management and administrative staff, along with certain initial opening, marketing and start-up costs, were essentially unchanged at staff increased to $4.8 million for the year ended December 31, 2025 as compared to approximately $4.2 million for the year ended December 31, 2024 as compared to approximately $4.3 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
As a result of this transaction, we recorded a loss on the extinguishment of the Hayfin Credit Facility in the amount of $26.2 million in during the year ended December 31, 2023, which is mainly comprised we recorded a total loss on the extinguishment in the amount of the write-off of unamortized debt discount and the prepayment penalty. $26.2 million.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
However, in the event that we pay paid down an aggregate amount under the revolving facility that is was greater than 50% of revolving facility the $72.5 million commitment of $72.5 million, amount, or $36,250,000, we will were still be required to pay an amount of interest on 50% of this amount, or $36.3 million, the revolving facility that would have been payable had $36,250,000 been outstanding, through the term of Ares Credit Facility. Maturity Date.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Other income, net, for the year ended December 31, 2024 was $1.9 million, as compared to $1.3 We recorded total revenues of $426.5 million for the year ended December 31, 2023. 2024, as compared to $258.2 million for the year ended December 31, 2023, an increase of $168.2 million, or 65%.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Cash provided by The improvement in cash flow from operations during the year ended December 2024, compared to that for the year ended December 31, 2024 was $118.7 million, as compared 2023, is primarily due to $8.8 million for the year ended December 31, 2023. substantially higher net income.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
We anticipate filing In June 2025, we filed our supplemental Biologics License Application (“sBLA”) in mid-2025, with potential FDA approval in the first half of 2026 sBLA for the expansion of ASCENIV’s label to include the pediatric setting for patients who are two years and older. older and we anticipate potential FDA approval in the first half of 2026.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Cost of product revenue was $217.4 million for the year ended December 31, 2025, as compared to $206.9 million for the year ended December 31, 2024, as compared to $169.3 million for the year ended December 31, 2023. an increase of $10.5 million, or 5%.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2025 2024 2023 (in thousands) 2024 2023 2022 Net cash provided by (used in) operating activities $ 50,396 $ 118,672 $ 8,800 $ (59,508) Net cash used in investing activities (21,891) (8,575) (4,981) (13,911) Net cash (used in) provided by used in financing activities (44,022) (58,302) (38,989) 108,852 Net change in cash and cash equivalents (15,517) 51,795 (35,170) 35,433 Cash and cash equivalents - beginning of year 103,147 51,352 86,522 51,089 Cash and cash equivalents - end of year $ 87,630 $ 103,147 $ 51,352 $ 86,522
Read it in 10-K Feb 25, 2026 at sec.gov
Quiet changesMD&A
In the future however, future, we may elect to work with the FDA and the immunology and infectious disease community to design an appropriate clinical trial to evaluate the use of ASCENIV in this patient population.
Read it in 10-K Feb 25, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADMA/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.